828
Views
28
CrossRef citations to date
0
Altmetric
Drug Evaluations

Update on romosozumab: a humanized monoclonal antibody to sclerostin

, & , MD

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Wipawadee Yooin, Chalermpong Saenjum, Jetsada Ruangsuriya & Supat Jiranusornkul. (2020) Discovery of potential sclerostin inhibitors from plants with loop2 region of sclerostin inhibition by interacting with residues outside Pro-Asn-Ala-Ile-Gly motif. Journal of Biomolecular Structure and Dynamics 38:5, pages 1272-1282.
Read now
Arti D Shah, Dolores Shoback & E Michael Lewiecki. (2015) Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. International Journal of Women's Health 7, pages 565-580.
Read now
Salvatore Minisola. (2014) Romosozumab: from basic to clinical aspects. Expert Opinion on Biological Therapy 14:9, pages 1225-1228.
Read now

Articles from other publishers (25)

Sara Kaveh, Hossein Hosseinifard, Nashmil Ghadimi, Mahdi Vojdanian & Aidin Aryankhesal. (2020) Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clinical Rheumatology 39:11, pages 3261-3276.
Crossref
Bart O. Williams & Mark L. Johnson. 2020. Principles of Bone Biology. Principles of Bone Biology 177 204 .
Shuxian Lin, Mohammad Mujtaba Methani & Jian Q. Feng. 2019. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Salvatore Minisola. 2019. Postmenopausal Diseases and Disorders. Postmenopausal Diseases and Disorders 387 394 .
Barbara Siegenthaler, Chafik Ghayor, Bebeka Gjoksi-Cosandey, Nisarat Ruangsawasdi & Franz Weber. (2018) The Bromodomain Inhibitor N-Methyl pyrrolidone Prevents Osteoporosis and BMP-Triggered Sclerostin Expression in Osteocytes. International Journal of Molecular Sciences 19:11, pages 3332.
Crossref
Heather Fairfield, Carolyne Falank, Elizabeth Harris, Victoria Demambro, Michelle McDonald, Jessica A. Pettitt, Sindhu T. Mohanty, Peter Croucher, Ina Kramer, Michaela Kneissel, Clifford J. Rosen & Michaela R. Reagan. (2017) The skeletal cell‐derived molecule sclerostin drives bone marrow adipogenesis. Journal of Cellular Physiology 233:2, pages 1156-1167.
Crossref
Anne-Margaux Collignon, Julie Lesieur, Christian Vacher, Catherine Chaussain & Gael Y. Rochefort. (2017) Strategies Developed to Induce, Direct, and Potentiate Bone Healing. Frontiers in Physiology 8.
Crossref
Salvatore Minisola, Cristiana Cipriani, Marco Occhiuto & Jessica Pepe. (2017) New anabolic therapies for osteoporosis. Internal and Emergency Medicine 12:7, pages 915-921.
Crossref
Bart O. Williams. (2017) LRP5: From bedside to bench to bone. Bone 102, pages 26-30.
Crossref
Xiaoou Diao, Zhirui Li, Baili An, Haitao Xin, Yulu Wu, Kai Li, Fan Feng & Chenyun Dou. (2017) The Microdamage and Expression of Sclerostin in Peri-implant Bone under One-time Shock Force Generated by Impact. Scientific Reports 7:1.
Crossref
Min Ge, Yingzhi Wu, Ronghu Ke, Tianyi Cai, Junyi Yang & Xiongzheng Mu. (2017) Value of Osteoblast-Derived Exosomes in Bone Diseases. Journal of Craniofacial Surgery 28:4, pages 866-870.
Crossref
Smriti Murali KrishnaSai-Wang SetoRoby J. JoseJiaze LiSusan K. MortonErik BirosYutang WangVianne NsengiyumvaJan H.N. LindemanGabriela G. LootsCatherine M. RushJeffrey M. CraigJonathan Golledge. (2017) Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II–Induced Aortic Aneurysm and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 37:3, pages 553-566.
Crossref
Erin Gaffney-Stomberg, Michael R. MacArthur & James P. McClung. 2017. Biomarkers in Bone Disease. Biomarkers in Bone Disease 443 461 .
Hailin Yang, Jinbo Dong, Wei Xiong, Zhong Fang, Hanfeng Guan & Feng Li. (2016) N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction. Annals of the New York Academy of Sciences 1385:1, pages 41-52.
Crossref
Jia Shen, Carolyn A. Meyers, Swati Shrestha, Arun Singh, Greg LaChaud, Vi Nguyen, Greg Asatrian, Noah Federman, Nicholas Bernthal, Fritz C. Eilber, Sarah M. Dry, Kang Ting, Chia Soo & Aaron W. James. (2016) Sclerostin expression in skeletal sarcomas. Human Pathology 58, pages 24-34.
Crossref
Yinshi Ren, Xianglong Han, Yan Jing, Baozhi Yuan, Huazhu Ke, Min Liu & Jian Q. Feng. (2016) Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23. Matrix Biology 52-54, pages 151-161.
Crossref
Changjun Li, Weishan Wang, Liang Xie, Xianghang Luo, Xu Cao & Mei Wan. (2016) Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression . Annals of the New York Academy of Sciences 1364:1, pages 62-73.
Crossref
J.A. Gasser. (2016) Therapy for musculoskeletal disorders. Journal of Orthopaedic Translation 4, pages 71-74.
Crossref
Erin Gaffney-Stomberg, Michael R. MacArthur & James P. McClung. 2016. Biomarkers in Bone Disease. Biomarkers in Bone Disease 1 19 .
Elena Tsourdi, Eddy Rijntjes, Josef Köhrle, Lorenz C. Hofbauer & Martina Rauner. (2015) Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1. Endocrinology 156:10, pages 3517-3527.
Crossref
Yinshi Ren, Xianglong Han, Sunita P. Ho, Stephen E. Harris, Zhengguo Cao, Aris N. Economides, Chunlin Qin, Huazhu Ke, Min Liu & Jian Q. Feng. (2015) Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model. The FASEB Journal 29:7, pages 2702-2711.
Crossref
Aline G. Costa, John P. Bilezikian & E. Michael Lewiecki. (2015) The potential use of antisclerostin therapy in chronic kidney disease ? mineral and bone disorder. Current Opinion in Nephrology and Hypertension, pages 1.
Crossref
N. Lara-Castillo & M. L. Johnson. (2015) LRP receptor family member associated bone disease. Reviews in Endocrine and Metabolic Disorders 16:2, pages 141-148.
Crossref
Maryam Sharifi, Lisa Ereifej & E. Michael Lewiecki. (2015) Sclerostin and skeletal health. Reviews in Endocrine and Metabolic Disorders 16:2, pages 149-156.
Crossref
Bart L. Clarke. (2014) Anti-sclerostin antibodies: Utility in treatment of osteoporosis. Maturitas 78:3, pages 199-204.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.